The impact of the HIV reverse transcriptase M184V mutation in combination with single thymidine analogue mutations on nucleoside reverse transcriptase inhibitor resistance in clinical samples from a large patient database

被引：0
|
作者：
Ross, L
Parkin, N
Bates, M
Fisher, R
St Clair, M
Tisdale, M
Lanier, R
机构：
[1] GlaxoSmithKline Inc, Res Triangle Pk, NC USA
[2] GlaxoSmithKline Inc, Stevenage, Herts, England
来源：
ANTIVIRAL THERAPY | 2003年 / 8卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
141
引用
收藏
页码：U134 / U135
页数：2
相关论文
共 50 条
  • [1] Phenotypic impact of HIV reverse transcriptase M1841/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance
    Ross, L
    Parkin, N
    Chappey, C
    Fisher, R
    Clair, MS
    Bates, M
    Tisdale, M
    Lanier, ER
    AIDS, 2004, 18 (12) : 1691 - 1696
  • [2] Reverse transcriptase M184V resistance mutation: back to the future?
    Teyssou, E.
    Soulie, C.
    Palich, R.
    Nouchi, A.
    Abdi, B.
    Katlama, C.
    Wirden, M.
    Pourcher, V.
    Marcelin, A.
    Calvez, V.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 196 - 197
  • [3] Does the M184V resistance mutation in reverse transcriptase reduce HIV transmission?
    Turner, D.
    HIV MEDICINE, 2011, 12 (04) : 193 - 194
  • [4] Reverse transcriptase mutation M184V delays the selection of thymidine-analogue mutations in children infected with subtype-C HIV-1
    Averbuch, D
    Schapiro, JM
    Engelhard, D
    Gradstein, S
    Gottesman, G
    Kedem, E
    Einhorn, M
    Grisaru-Soen, G
    Ofir, M
    Milguir, F
    Rudich, H
    Ram, D
    Grossman, Z
    ANTIVIRAL THERAPY, 2004, 9 (04) : U114 - U115
  • [5] Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir
    Byun, Hyeonah
    Papathanasopoulos, Maria Antonia
    Steegen, Kim
    Basson, Adriaan Erasmus
    VIRUSES-BASEL, 2024, 16 (12):
  • [6] Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients
    Winters, MA
    Bosch, RJ
    Albrecht, MA
    Katzenstein, DA
    JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (04): : 537 - 540
  • [7] New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T)
    Pouga, Lydia
    Santoro, Maria Mercedes
    Charpentier, Charlotte
    Di Carlo, Domenico
    Romeo, Isabella
    Artese, Anna
    Alcaro, Stefano
    Antinori, Andrea
    Wirden, Marc
    Perno, Carlo Federico
    Ambrosio, Francesca Alessandra
    Calvez, Vincent
    Descamps, Diane
    Marcelin, Anne-Genevieve
    Ceccherini-Silberstein, Francesca
    Lambert-Niclot, Sidonie
    CHEMICAL BIOLOGY & DRUG DESIGN, 2019, 93 (01) : 50 - 59
  • [8] Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase
    Diallo, K
    Götte, M
    Wainberg, MA
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (11) : 3377 - 3383
  • [9] The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors
    Miller, V
    Stürmer, M
    Staszewski, S
    Gröschel, B
    Hertogs, K
    de Béthune, MP
    Pauwels, R
    Harrigan, PR
    Bloor, S
    Kemp, SD
    Larder, BA
    AIDS, 1998, 12 (07) : 705 - 712
  • [10] Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1
    Turner, D
    Brenner, B
    Wainberg, MA
    CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2003, 10 (06) : 979 - 981
12345